Funding for this research was provided by:
This work was supported by Eisai Inc., Woodcliff Lake, NJ
Text and Data Mining valid from 2019-05-01
Received: 27 December 2018
Revised: 14 March 2019
Accepted: 5 April 2019
First Online: 8 May 2019
: J.-Y.B. has received research support and honoraria from Eisai. P.S. has received translational research support, travel support and honoraria for advisory and educational functions from Eisai. S.B. has received honoraria from Novartis and participated in an advisory board; has received honoraria from PharmaMar; grants and personal fees from Blueprint Medicines; has participated in advisory boards for Eli Lilly and Deciphera; and has received grants from Incyte. D.R.D. and Y.J. are employees of Eisai Inc. R.G.M. has received research support from Eisai Inc. The remaining authors declare no competing interests.
: There is no identifying patient information in this article. In addition, all authors confirm that this manuscript can be considered for publication.
: The study was conducted in accordance with the Declaration of Helsinki and guidelines of the International Conference for Harmonization/Good Clinical Practice and was approved by the respective institutional research ethics boards of each participating site (see Supplementary Table 1). All patients provided written informed consent prior to undergoing any study-related procedure.
: The data of this study are considered commercially proprietary and are not stored for unrestricted access. All the authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.